文献速递糖尿病

利用人工智能和机器学习加速1型糖尿病疾病修饰疗法的发现

Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes.
PubMed 文献 · Diabetologia · 2024-12-19

本文综述了利用人工智能和机器学习加速1型糖尿病疾病修饰疗法发现的新兴方法,包括药物重定位、协同组合筛选、多组学技术发现新型生物标志物及抗原特异性免疫治疗,以及构建「数字孪生」模型进行个性化药物的快速计算机模拟测试和剂量确定。同时讨论了人工智能和机器学习的局限性,包括模型可解释性和偏倚问题,以及仍需通过确证性干预试验进行验证。

要点

  • 人工智能和机器学习可加速1型糖尿病药物重定位和协同组合筛选。
  • 多组学技术(包括抗原加工和呈递分析)可能发现新型生物标志物并转化为抗原特异性免疫治疗。
  • 人工智能可构建「数字孪生」模型用于个性化药物的快速计算机模拟测试和剂量确定。

核心结论

  • 人工智能和机器学习的新兴方法有望加速1型糖尿病疾病修饰疗法的发现和疗效测试。
  • 人工智能和机器学习存在模型可解释性和偏倚等局限性,仍需通过确证性干预试验进行验证。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • 经典安慰剂对照干预试验常采用单药治疗、广泛参与者人群和以临床终点为重点的延长随访期。
  • 新兴方法包括重定位用于治疗与1型糖尿病共享致病通路的疾病的药物,以及选择协同药物组合以最大化疗效。
  • 多组学技术(包括分析抗原加工和呈递给适应性免疫细胞)可能发现新型生物标志物,并转化为抗原特异性免疫治疗。
  • 人工智能可用于创建「数字孪生」模型,实现个性化药物的快速计算机模拟测试和剂量确定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 人工智能和机器学习存在模型可解释性和偏倚相关的问题。
  • 仍需通过确证性干预试验进行验证研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Progress in developing therapies for the maintenance of endogenous insulin secretion in, or the prevention of, type 1 diabetes has been hindered by limited animal models, the length and cost of clinical trials, difficulties in identifying individuals who will progress faster to a clinical diagnosis of type 1 diabetes, and heterogeneous clinical responses in intervention trials. Classic placebo-controlled intervention trials often include monotherapies, broad participant populations and extended follow-up periods focused on clinical endpoints. While this approach remains the 'gold standard' of clinical research, efforts are underway to implement new approaches harnessing the power of artificial intelligence and machine learning to accelerate drug discovery and efficacy testing. Here, we review emerging approaches for repurposing agents used to treat diseases that share pathogenic pathways with type 1 diabetes and selecting synergistic combinations of drugs to maximise therapeutic efficacy. We discuss how emerging multi-omics technologies, including analysis of antigen processing and presentation to adaptive immune cells, may lead to the discovery of novel biomarkers and subsequent translation into antigen-specific immunotherapies. We also discuss the potential for using artificial intelligence to create 'digital twin' models that enable rapid in silico testing of personalised agents as well as dose determination. To conclude, we discuss some limitations of artificial intelligence and machine learning, including issues pertaining to model interpretability and bias, as well as the continued need for validation studies via confirmatory intervention trials.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Shapiro MR, Tallon EM, Brown ME, et al. Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes. Diabetologia. 2024. PMID: 39694914. doi:10.1007/s00125-024-06339-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。